Genetic and Clinical-epidemiologic Profile of hRSV in Pediatric Patients in Southern Brazil: A Four-year Hospital

Sonia Mara Raboni1,2, Heloisa I G Giamberardino3, Jucelia S Santos1

  • 1From the Molecular Virology Research Laboratory, Universidade Federal do Paraná, Curitiba, Brazil.

Insights

Human respiratory syncytial virus (hRSV) molecular epidemiology in children revealed distinct hRSV-A and hRSV-B genotypes. Certain hRSV-B genotypes (GB5.0.2, GB5.0.4a) were linked to more severe illness in young patients.

Area of Science:

  • Virology
  • Epidemiology
  • Pediatrics

Background:

  • Human respiratory syncytial virus (hRSV) is a major cause of acute respiratory illness and hospitalization in children.
  • Understanding hRSV molecular epidemiology and its clinical associations is vital for public health.

Purpose of the Study:

  • To examine the molecular epidemiology of hRSV in a pediatric cohort over four years.
  • To describe the interrelationship between hRSV genotypes and clinical data.

Main Methods:

  • A cross-sectional study analyzed respiratory samples from children with acute respiratory illness between 2014 and 2017.
  • Respiratory viruses were detected using multiplex real-time polymerase chain reaction, and molecular typing was performed by nucleotide sequencing of the G gene.

Main Results:

  • Of 353 children with hRSV, 207 underwent G gene sequencing. hRSV-B was detected in 53% and hRSV-A in 47% of cases.
  • hRSV-A sequences were ON1-like (GA2.3.5), while hRSV-B sequences were BA-like with three lineages (GB5.0.2, GB5.0.4a, GB5.0.5a).
  • Severe cases were more frequent in younger children and those infected with hRSV-B GB5.0.2 and GB5.0.4a genotypes, with no significant link to comorbidities.

Conclusions:

  • Both hRSV subtypes exhibited similar severity, unrelated to comorbidities.
  • Younger age and specific hRSV-B genotypes (GB5.0.2, GB5.0.4a) were associated with more severe outcomes.
  • Monitoring hRSV molecular evolution is crucial for tracking variants and evaluating the efficacy of vaccines and monoclonal antibodies.
Abstract